GSK plc
GSK is a global biopharmaceutical company headquartered in London. It develops and supplies medicines, including Specialty Medicines and respiratory medicines, and invests in new product development and launches. Its operations include manufacturing facilities and worldwide supply chains. GSK also has a relationship with ViiV Healthcare and holds equity stakes in companies with which it has research collaborations, providing access to biotechnology developments. It makes money from medicine sales, including prescription medicines supplied to patients.
No SEC Form 4 filings for $GSK in the last 30 days.
See all $GSK insider activity →The FDA approved a label update for GlaxoSmithKline's BENLYSTA (belimumab) under BLA 761043 on 10/30/2026. The update does not include new indications or pricing details, and the specific changes are not disclosed.
Alamar Biosciences (ALMR) and GSK (GSK) announced a collaboration to study disease progression and treatment response using Alamar's NULISA platform. The study will analyze 60,000 serum samples across respiratory, liver, kidney, neurological, and autoimmune conditions. The goal is to identify protein signatures for earlier disease detection and precision treatment.
GlaxoSmithKline Pharmaceuticals reported a 30.4% YoY rise in net profit to ₹336 crore for Q2, with revenue up 20.8% to ₹1,184 crore. Growth was driven by strong performance in General Medicines, Vaccines, and Specialty Medicines portfolios, along with contributions from the Oncology business. EBITDA rose 19.8% to ₹402 crore, though margins slightly decreased. The company cited supply chain resilience and strategic initiatives as key factors.
Over the past 7 days, AlphAI's AI scored 20 news stories mentioning GSK (GSK plc). Coverage has skewed bullish: 10 bullish, 4 neutral, and 6 bearish.
Recent GSK coverage spans regulation, earnings and financial news.
Label update may cause modest price movement as investors assess any changes.
The partnership could enhance GSK's biomarker discovery and precision‑medicine programs, offering modest upside potential.
Earnings beat expectations with strong profit growth.
Approval likely lifts GSK share price on the back of a novel hepatitis‑B cure.
Downgrade may weigh on the stock in the short term.
AlphAI scores every news story that mentions GSK with an AI model for sentiment and relevance, and aggregates insider trades from GSK plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA approved a label update for GlaxoSmithKline's BENLYSTA (belimumab) under BLA 761043 on 10/30/2026. The update does not include new indications or pricing details, and the specific changes are not disclosed.
1 min readAlamar Biosciences (ALMR) and GSK (GSK) announced a collaboration to study disease progression and treatment response using Alamar's NULISA platform. The study will analyze 60,000 serum samples across respiratory, liver, kidney, neurological, and autoimmune conditions. The goal is to identify protein signatures for earlier disease detection and precision treatment.
2 min readGlaxoSmithKline Pharmaceuticals reported a 30.4% YoY rise in net profit to ₹336 crore for Q2, with revenue up 20.8% to ₹1,184 crore. Growth was driven by strong performance in General Medicines, Vaccines, and Specialty Medicines portfolios, along with contributions from the Oncology business. EBITDA rose 19.8% to ₹402 crore, though margins slightly decreased. The company cited supply chain resilience and strategic initiatives as key factors.
2 min readGSK's Hibsago (bepirovirsen) approved in Canada for chronic hepatitis B, offering a finite treatment option. Approval based on Phase III trials showing 19-26% functional cure rates. Targets 262,000 Canadians with chronic hepatitis B, a leading cause of liver cancer. Supply expected in early 2027.
3 min readBerenberg downgraded Haleon to 'Hold' and cut its target to 365p after the company lowered its growth guidance. Jefferies downgraded GSK to 'Hold' following its Q3 results. Citigroup and UBS raised Shell's targets after its Q3 beat and increased buyback. Deutsche Bank downgraded J Sainsbury to 'Hold' ahead of Christmas trading. Shore Capital upgraded HSBC to 'Hold' after its share price fell.
3 min readThe FTSE 100 fell 0.25% as oil majors BP and Shell declined with crude prices. Brent dropped 3.2% to $109.86, WTI fell 3.5% to $100.45. Glencore proposed CEO pay changes, Ryanair warned of potential pay freezes, and TotalEnergies acquired stakes in Malaysian gas fields. BP completed the sale of a 65% stake in Castrol.
6 min readGSK reported Q3 revenue and core profit gains, with GAAP EPS of 39p and £1.54bn net income. The company launched a £1.9bn cost-cutting plan, completed a $10.6bn acquisition of Nuvalent, and received FDA approval for Hibsago. Vaccine sales were mixed, while specialty medicines, including HIV, oncology, and respiratory/immunology, saw increases. GSK plans 18 Phase III trials in 2026 and aims to double its clinical-stage oncology assets.
2 min readBoehringer Ingelheim partners with Microsoft to explore AI in clinical development. NVIDIA announces healthcare collaborations at GTC Berlin. GSK presents positive clinical trial results for cancer treatments. The Lancet warns of accelerating health impacts from climate change.
3 min readOctober FDA approvals include Novartis' remibrutinib for dermographism, Teva's once-monthly olanzapine for schizophrenia, Genentech's satralizumab for thyroid eye disease, GSK's bepirovirsen for chronic HBV, and AbbVie's risankizumab for Crohn disease. Each approval offers new treatment options and was based on clinical trial data.
3 min readGSK shares rose 2.26% to £18.55 on Friday, outperforming the FTSE 100's 0.07% gain. The stock remains 18.71% below its 52-week high of £22.82.
1 min read
